Free Trial

Celldex Therapeutics (CLDX) News Today

$36.22
-0.70 (-1.90%)
(As of 10:36 AM ET)
Charles Schwab Investment Management Inc. Acquires 47,844 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Charles Schwab Investment Management Inc. raised its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 409,391 shares of the biopharmaceutical company's stoc
Assenagon Asset Management S.A. Buys Shares of 90,931 Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Assenagon Asset Management S.A. bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 90,931 shares of the biopharmaceutical
Celldex Therapeutics (NASDAQ:CLDX) Receives "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Wednesday.
Brokers Issue Forecasts for Celldex Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:CLDX)
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for Celldex Therapeutics in a research note issued on Tuesday, May 7th. Lifesci Capital analyst S. Slutsky expects that the biopharmaceutic
Unveiling 4 Analyst Insights On Celldex Therapeutics
Celldex Therapeutics (NASDAQ:CLDX) Earns Buy Rating from HC Wainwright
HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday.
Celldex Therapeutics (NASDAQ:CLDX) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday.
Celldex Therapeutics (NASDAQ:CLDX) Trading 2.7% Higher
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Up 2.7%
DekaBank Deutsche Girozentrale Acquires Shares of 25,000 Celldex Therapeutics, Inc. (NASDAQ:CLDX)
DekaBank Deutsche Girozentrale bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 25,000 shares of the biopharmaceu
CLDX Celldex Therapeutics, Inc.
Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 8.0%
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the target of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 5,900,000 shares, a drop of 8.0% from the February 29th total of 6,410,000 shares. Based on an average daily trading volume, of 927,100 shares, the short-interest ratio is currently 6.4 days.
SG Americas Securities LLC Sells 31,928 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)
SG Americas Securities LLC reduced its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 40.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 46,083 shares of the biopharmaceutical company'
Cantor Fitzgerald Reiterates "Overweight" Rating for Celldex Therapeutics (NASDAQ:CLDX)
Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) saw a significant decrease in short interest during the month of February. As of February 29th, there was short interest totalling 6,410,000 shares, a decrease of 7.6% from the February 14th total of 6,940,000 shares. Based on an average daily trading volume, of 863,900 shares, the days-to-cover ratio is presently 7.4 days.
CLDX Aug 2024 70.000 call
Wellington Management Group LLP Buys 300,406 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Wellington Management Group LLP grew its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 5.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,431,833 shares of the biopharmaceutical compa
CLDX Apr 2024 65.000 call
CLDX Aug 2024 50.000 call
CLDX Apr 2024 40.000 call
CLDX Jan 2025 15.000 put
GSA Capital Partners LLP Increases Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)
GSA Capital Partners LLP lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 192.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 44,716 shares of the biopharmaceutical company's stock after purchasing
CLDX Jan 2025 30.000 put
CLDX Jan 2025 70.000 call
Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week High at $53.18
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month High at $53.18
Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume
Celldex Therapeutics (NASDAQ:CLDX) Sees Strong Trading Volume
Q1 2024 EPS Estimates for Celldex Therapeutics, Inc. Raised by Leerink Partnrs (NASDAQ:CLDX)
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at Leerink Partnrs raised their Q1 2024 earnings per share (EPS) estimates for Celldex Therapeutics in a report issued on Wednesday, February 28th. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical
Charles Schwab Investment Management Inc. Buys 10,818 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Charles Schwab Investment Management Inc. increased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 3.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 361,547 shar
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Eventide Asset Management LLC
Eventide Asset Management LLC boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 16.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,600,000 shares of the biopharmaceutical company's stock aft
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Expected to Earn FY2028 Earnings of $2.25 Per Share
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at Leerink Partnrs dropped their FY2028 earnings estimates for shares of Celldex Therapeutics in a research report issued on Wednesday, February 28th. Leerink Partnrs analyst T. Smith now anticipates that the biopharmaceut
Get Celldex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

Digitizing the $11T commodities sector with one tiny stock (Ad)

One tiny company — trading completely undiscovered around 15-cents per share — has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector.

It’s an opportunity that likely won’t stay at these levels for long

CLDX Media Mentions By Week

CLDX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CLDX
News Sentiment

1.33

0.92

Average
Medical
News Sentiment

CLDX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CLDX Articles
This Week

3

2

CLDX Articles
Average Week

Get Celldex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CLDX) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners